Impact of Furocyst on Lipid Levels and Insulin Resistance in Women with PCOS
Author Information
Author(s): Muacevic Alexander, Adler John R, Shukla Aparna, Singh Renu, Gupta Anuraag, Goel Apurva, Tiwari Kiran, Singh Satyendra K
Primary Institution: Centre for Advanced Research, King George's Medical University, Lucknow, IND
Hypothesis
Does Furocyst improve lipid profiles and insulin resistance in women with PCOS across different BMI categories?
Conclusion
Furocyst significantly improves insulin sensitivity and lipid profiles in women with PCOS, especially in those who are overweight or obese.
Supporting Evidence
- Furocyst reduced mean BMI significantly in obese patients.
- HOMA-IR index decreased across all BMI categories in the Furocyst group.
- Total cholesterol, triglycerides, and VLDL levels were significantly lowered in patients taking Furocyst.
- LDL-HDL and cholesterol-HDL ratios improved significantly in obese patients.
- Furocyst showed no significant effect on HDL levels.
Takeaway
Furocyst, a supplement made from fenugreek seeds, helps women with PCOS feel better by lowering their cholesterol and improving how their bodies use insulin.
Methodology
A single-blinded, randomized clinical trial with 230 patients aged 18-45, comparing Furocyst to placebo over 12 weeks.
Potential Biases
Potential bias due to funding from the manufacturer of Furocyst.
Limitations
Short treatment duration of 12 weeks and significant dropout rate, particularly in the placebo group.
Participant Demographics
Women aged 18-45 with PCOS, including normal weight, overweight, and obese categories.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website